EMA's Decision On Ranitidine Remaining Available Could Come At End Of April
Executive Summary
Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.
You may also be interested in...
Why US FDA Requested Ranitidine Withdrawal, And How Other Drugs Could Follow
FDA made request after finding unacceptable levels of nitrosamine NDMA can form during storage above room temperature or beyond expiry. Forthcoming guidance on detecting impurities like nitrosamines in any drug will call for routine testing as well as a chemical risk assessment “to look at what is the probability of generating them.
Why The US FDA Requested Ranitidine Withdrawal; How Other Withdrawals Could Follow
Agency worried what might happen beyond expiry or room temperature to generate carcinogenic impurities in ranitidine; will guide assessment of nitrosamine risks in other drugs.
More Time For EU Nitrosamine Evaluations Due To COVID-19
Citing challenges posed by the COVID-19 pandemic, EU regulators have extended the deadline for companies to finish nitrosamine-related risk evaluations.